Serkan Keskin1, Ali Cevat Kutluk2, Faruk Tas3. 1. Department of Medical Oncology, Memorial Hospital, Istanbul, Turkey. Email: drkeskin76@hotmail.com 2. Department of Thoracic Surgery, Yedikule Education and Research Hospital, Istanbul, Turkey. 3. Department of Medical Oncology, Istanbul University, Istanbul, Turkey.
Abstract
Objective: Despite the existence of detailed consensus guidelines, challenges remain regarding the role angiogenetic factors on non-small cell lung cancer (NSCLC). This study was conducted to determine the role of the vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and angiopoietin2 (Ang2) in patients with NSCLC. Methods: This study included 64 consecutive patients with non-small cell lung cancer, who admitted to clinic. Pre-treatment serum VEGF, IL-8 and Ang2 levels were evaluated. Patients were treated according to internationally accepted guidelines. Results: VEGF and IL-8 serum levels of patients with both squamous cell carcinoma and adenocarcinoma were significantly higher than controls (p<0.05). In addition, IL-8 levels were lower among treatment-responders than non-responders (p:0.031). Impact of elevated or decreased levels of VEGF, Ang2 and IL-8 on survival was evaluated, accepting median level as reference. There was no correlation between the serum levels of VEGF, Ang2, IL-8 and survival. Conclusion: We found that the levels of angiogenic markers were significantly different between non-small cell lung cancer patients and controls. These markers could elicit more information related to stage and prognosis. Creative Commons Attribution License
Objective: Despite the existence of detailed consensus guidelines, challenges remain regarding the role angiogenetic factors on non-small cell lung cancer (NSCLC). This study was conducted to determine the role of the vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and angiopoietin2 (Ang2) in patients with NSCLC. Methods: This study included 64 consecutive patients with non-small cell lung cancer, who admitted to clinic. Pre-treatment serum VEGF, IL-8 and Ang2 levels were evaluated. Patients were treated according to internationally accepted guidelines. Results:VEGF and IL-8 serum levels of patients with both squamous cell carcinoma and adenocarcinoma were significantly higher than controls (p<0.05). In addition, IL-8 levels were lower among treatment-responders than non-responders (p:0.031). Impact of elevated or decreased levels of VEGF, Ang2 and IL-8 on survival was evaluated, accepting median level as reference. There was no correlation between the serum levels of VEGF, Ang2, IL-8 and survival. Conclusion: We found that the levels of angiogenic markers were significantly different between non-small cell lung cancerpatients and controls. These markers could elicit more information related to stage and prognosis. Creative Commons Attribution License
Authors: D Masuya; C Huang; D Liu; K Kameyama; E Hayashi; A Yamauchi; S Kobayashi; R Haba; H Yokomise Journal: Cancer Date: 2001-11-15 Impact factor: 6.860
Authors: Y Yamamoto; M Toi; S Kondo; T Matsumoto; H Suzuki; M Kitamura; K Tsuruta; T Taniguchi; A Okamoto; T Mori; M Yoshida; T Ikeda; T Tominaga Journal: Clin Cancer Res Date: 1996-05 Impact factor: 12.531